ID   PRIO_HUMAN              Reviewed;         253 AA.
AC   P04156; O60489; P78446; Q15216; Q15221; Q27H91; Q5QPB4; Q8TBG0;
AC   Q96E70; Q9UP19;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   22-JUL-2015, entry version 203.
DE   RecName: Full=Major prion protein;
DE            Short=PrP;
DE   AltName: Full=ASCR;
DE   AltName: Full=PrP27-30;
DE   AltName: Full=PrP33-35C;
DE   AltName: CD_antigen=CD230;
DE   Flags: Precursor;
GN   Name=PRNP; Synonyms=ALTPRP, PRIP, PRP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3755672; DOI=10.1089/dna.1986.5.315;
RA   Kretzschmar H.A., Stowring L.E., Westaway D., Stubblebine W.H.,
RA   Prusiner S.B., Dearmond S.J.;
RT   "Molecular cloning of a human prion protein cDNA.";
RL   DNA 5:315-324(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 56-GLY--GLY-63 DEL.
RC   TISSUE=Brain;
RX   PubMed=1678248;
RA   Puckett C., Concannon P., Casey C., Hood L.E.;
RT   "Genomic structure of the human prion protein gene.";
RL   Am. J. Hum. Genet. 49:320-329(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9799790;
RA   Lee I.Y., Westaway D., Smit A.F.A., Wang K., Seto J., Chen L.,
RA   Acharya C., Ankener M., Baskin D., Cooper C., Yao H., Prusiner S.B.,
RA   Hood L.E.;
RT   "Complete genomic sequence and analysis of the prion protein gene
RT   region from three mammalian species.";
RL   Genome Res. 8:1022-1037(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GSD ARG-187.
RC   TISSUE=Blood;
RX   PubMed=10581485;
RX   DOI=10.1002/(SICI)1096-8628(19991215)88:6<653::AID-AJMG14>3.0.CO;2-E;
RA   Cervenakova L., Buetefisch C., Lee H.S., Taller I., Stone G.,
RA   Gibbs C.J. Jr., Brown P., Hallett M., Goldfarb L.G.;
RT   "Novel PRNP sequence variant associated with familial
RT   encephalopathy.";
RL   Am. J. Med. Genet. 88:653-656(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Prostate;
RA   Hryb D.J., Reynolds T.A., Nakhla A.M., Kahn S.M., Khan S.M.,
RA   Romas N.A., Rosner W.;
RT   "Cloning of human prostate prion protein cDNA.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Zhang J., Liu Y., Chen H., Jiang H., Lu W., Zhu X., Xie Q., Cai X.,
RA   Liu X.;
RT   "Analysis and comparison of several mammalian prion protein genes
RT   Prnp.";
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-253.
RX   PubMed=3014653; DOI=10.1126/science.3014653;
RA   Liao Y.-C.J., Lebo R.V., Clawson G.A., Smuckler E.A.;
RT   "Human prion protein cDNA: molecular cloning, chromosomal mapping, and
RT   biological implications.";
RL   Science 233:364-367(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 9-232, AND VARIANT 56-GLY--GLY-63
RP   DEL.
RC   TISSUE=Brain;
RX   PubMed=1363802; DOI=10.1093/hmg/1.6.443;
RA   Diedrich J.F., Knopman D.S., List J.F., Olson K., Frey W.H.,
RA   Emory C.R., Sung J.H., Haase A.T.;
RT   "Deletion in the prion protein gene in a demented patient.";
RL   Hum. Mol. Genet. 1:443-444(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 8-253, AND VARIANT
RP   SCHIZOAFFECTIVE DISORDER SER-171.
RX   PubMed=9384372; DOI=10.1038/36757;
RA   Samaia H.B., Mari J.J., Vallada H.P., Moura R.P., Simpson A.J.G.,
RA   Brentani R.R.;
RT   "A prion-linked psychiatric disorder.";
RL   Nature 390:241-241(1997).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-85, AND VARIANT 56-GLY--GLY-63
RP   DEL.
RX   PubMed=7485229; DOI=10.1002/ajmg.1320600104;
RA   Perry R.T., Go R.C., Harrell L.E., Acton R.T.;
RT   "SSCP analysis and sequencing of the human prion protein gene (PRNP)
RT   detects two different 24 bp deletions in an atypical Alzheimer's
RT   disease family.";
RL   Am. J. Med. Genet. 60:12-18(1995).
RN   [13]
RP   PROTEIN SEQUENCE OF 58-85 AND 111-150.
RX   PubMed=1672107;
RA   Tagliavini F., Prelli F., Ghiso J., Bugiani O., Serban D.,
RA   Prusiner S.B., Farlow M.R., Ghetti B., Frangione B.;
RT   "Amyloid protein of Gerstmann-Straussler-Scheinker disease (Indiana
RT   kindred) is an 11 kd fragment of prion protein with an N-terminal
RT   glycine at codon 58.";
RL   EMBO J. 10:513-519(1991).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 84-91.
RX   PubMed=1683708; DOI=10.1073/pnas.88.23.10926;
RA   Goldfarb L.G., Brown P., McCombie W.R., Goldgaber D., Swergold G.D.,
RA   Wills P.R., Cervenakova L., Baron H., Gibbs C.J. Jr., Gajdusek D.C.;
RT   "Transmissible familial Creutzfeldt-Jakob disease associated with
RT   five, seven, and eight extra octapeptide coding repeats in the PRNP
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10926-10930(1991).
RN   [15]
RP   COPPER-BINDING, AND FUNCTION.
RX   PubMed=12732622; DOI=10.1074/jbc.M300394200;
RA   Mani K., Cheng F., Havsmark B., Jonsson M., Belting M., Fransson L.A.;
RT   "Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support
RT   S-nitroso-dependent autocleavage of glypican-1 heparan sulfate.";
RL   J. Biol. Chem. 278:38956-38965(2003).
RN   [16]
RP   COPPER-BINDING.
RX   PubMed=16144413; DOI=10.1021/ja053254z;
RA   Chattopadhyay M., Walter E.D., Newell D.J., Jackson P.J.,
RA   Aronoff-Spencer E., Peisach J., Gerfen G.J., Bennett B.,
RA   Antholine W.E., Millhauser G.L.;
RT   "The octarepeat domain of the prion protein binds Cu(II) with three
RT   distinct coordination modes at pH 7.4.";
RL   J. Am. Chem. Soc. 127:12647-12656(2005).
RN   [17]
RP   COPPER-BINDING, AND ZINC-BINDING.
RX   PubMed=18034490; DOI=10.1021/ja077146j;
RA   Walter E.D., Stevens D.J., Visconte M.P., Millhauser G.L.;
RT   "The prion protein is a combined zinc and copper binding protein: Zn2+
RT   alters the distribution of Cu2+ coordination modes.";
RL   J. Am. Chem. Soc. 129:15440-15441(2007).
RN   [18]
RP   ALTERNATIVE INITIATION (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF MET-1 AND MET-8.
RX   PubMed=19059915; DOI=10.1074/jbc.M804051200;
RA   Juanes M.E., Elvira G., Garcia-Grande A., Calero M., Gasset M.;
RT   "Biosynthesis of prion protein nucleocytoplasmic isoforms by
RT   alternative initiation of translation.";
RL   J. Biol. Chem. 284:2787-2794(2009).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-197.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DISEASE ASSOCIATION.
RX   PubMed=19936054; DOI=10.1371/journal.ppat.1000666;
RA   Taylor D.R., Whitehouse I.J., Hooper N.M.;
RT   "Glypican-1 mediates both prion protein lipid raft association and
RT   disease isoform formation.";
RL   PLoS Pathog. 5:E1000666-E1000666(2009).
RN   [21]
RP   COPPER-BINDING.
RX   PubMed=19381258; DOI=10.1371/journal.ppat.1000390;
RA   Stevens D.J., Walter E.D., Rodriguez A., Draper D., Davies P.,
RA   Brown D.R., Millhauser G.L.;
RT   "Early onset prion disease from octarepeat expansion correlates with
RT   copper or zinc binding properties.";
RL   PLoS Pathog. 5:E1000390-E1000390(2009).
RN   [22]
RP   SUBUNIT, AND DOMAIN.
RX   PubMed=20375014; DOI=10.1074/jbc.M110.111815;
RA   Adrover M., Pauwels K., Prigent S., de Chiara C., Xu Z., Chapuis C.,
RA   Pastore A., Rezaei H.;
RT   "Prion fibrillization is mediated by a native structural element that
RT   comprises helices H2 and H3.";
RL   J. Biol. Chem. 285:21004-21012(2010).
RN   [23]
RP   COPPER-BINDING, CIRCULAR DICHROISM, DOMAIN, FUNCTION, AND SUBUNIT.
RX   PubMed=20564047; DOI=10.1002/jcb.22743;
RA   Wu D., Zhang W., Luo Q., Luo K., Huang L., Wang W., Huang T., Chen R.,
RA   Lin Y., Pang D., Xiao G.;
RT   "Copper (II) promotes the formation of soluble neurotoxic PrP
RT   oligomers in acidic environment.";
RL   J. Cell. Biochem. 111:627-633(2010).
RN   [24]
RP   INTERACTION WITH KIAA1191.
RX   PubMed=21153684; DOI=10.1007/s11010-010-0690-4;
RA   Mishra M., Inoue N., Heese K.;
RT   "Characterizing the novel protein p33MONOX.";
RL   Mol. Cell. Biochem. 350:127-134(2011).
RN   [25]
RP   STRUCTURE BY NMR OF 90-231 OF MUTANT LYS-200.
RX   PubMed=10954699; DOI=10.1074/jbc.C000483200;
RA   Zhang Y., Swietnicki W., Zagorski M.G., Surewicz W.K.,
RA   Soennichsen F.D.;
RT   "Solution structure of the E200K variant of human prion protein.
RT   Implications for the mechanism of pathogenesis in familial prion
RT   diseases.";
RL   J. Biol. Chem. 275:33650-33654(2000).
RN   [26]
RP   STRUCTURE BY NMR OF 23-230.
RX   PubMed=10618385; DOI=10.1073/pnas.97.1.145;
RA   Zahn R., Liu A., Luhrs T., Riek R., von Schroetter C.,
RA   Lopez Garcia F., Billeter M., Calzolai L., Wider G., Wuethrich K.;
RT   "NMR solution structure of the human prion protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:145-150(2000).
RN   [27]
RP   STRUCTURE BY NMR OF 118-221.
RX   PubMed=10900000; DOI=10.1073/pnas.97.15.8340;
RA   Calzolai L., Lysek D.A., Guntert P., von Schroetter C., Riek R.,
RA   Zahn R., Wuethrich K.;
RT   "NMR structures of three single-residue variants of the human prion
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8340-8345(2000).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 119-226, DOMAIN, AND SUBUNIT.
RX   PubMed=11524679; DOI=10.1038/nsb0901-770;
RA   Knaus K.J., Morillas M., Swietnicki W., Malone M., Surewicz W.K.,
RA   Yee V.C.;
RT   "Crystal structure of the human prion protein reveals a mechanism for
RT   oligomerization.";
RL   Nat. Struct. Biol. 8:770-774(2001).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (0.75 ANGSTROMS) OF 61-65 IN COMPLEX WITH COPPER
RP   ION, DOMAIN, AND SUBUNIT.
RX   PubMed=11900542; DOI=10.1021/bi011922x;
RA   Burns C.S., Aronoff-Spencer E., Dunham C.M., Lario P., Avdievich N.I.,
RA   Antholine W.E., Olmstead M.M., Vrielink A., Gerfen G.J., Peisach J.,
RA   Scott W.G., Millhauser G.L.;
RT   "Molecular features of the copper binding sites in the octarepeat
RT   domain of the prion protein.";
RL   Biochemistry 41:3991-4001(2002).
RN   [30]
RP   STRUCTURE BY NMR OF 61-68, DISULFIDE BOND, AND SUBUNIT.
RX   PubMed=14623188; DOI=10.1016/j.jmb.2003.09.048;
RA   Zahn R.;
RT   "The octapeptide repeats in mammalian prion protein constitute a pH-
RT   dependent folding and aggregation site.";
RL   J. Mol. Biol. 334:477-488(2003).
RN   [31]
RP   REVIEW ON VARIANTS.
RX   PubMed=8364585; DOI=10.1002/humu.1380020303;
RA   Palmer M.S., Collinge J.;
RT   "Mutations and polymorphisms in the prion protein gene.";
RL   Hum. Mutat. 2:168-173(1993).
RN   [32]
RP   REVIEW ON VARIANTS.
RX   PubMed=8105771; DOI=10.1001/archneur.1993.00540110011002;
RA   Prusiner S.B.;
RT   "Genetic and infectious prion diseases.";
RL   Arch. Neurol. 50:1129-1153(1993).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (0.85 ANGSTROMS) OF 170-175, SUBUNIT, AND
RP   DOMAIN.
RX   PubMed=17468747; DOI=10.1038/nature05695;
RA   Sawaya M.R., Sambashivan S., Nelson R., Ivanova M.I., Sievers S.A.,
RA   Apostol M.I., Thompson M.J., Balbirnie M., Wiltzius J.J.,
RA   McFarlane H.T., Madsen A.O., Riekel C., Eisenberg D.;
RT   "Atomic structures of amyloid cross-beta spines reveal varied steric
RT   zippers.";
RL   Nature 447:453-457(2007).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 119-231 IN COMPLEX WITH FAB
RP   FRAGMENT OF MONOCLONAL ANTIBODY ICSM 18, AND SUBUNIT.
RX   PubMed=19204296; DOI=10.1073/pnas.0809170106;
RA   Antonyuk S.V., Trevitt C.R., Strange R.W., Jackson G.S., Sangar D.,
RA   Batchelor M., Cooper S., Fraser C., Jones S., Georgiou T.,
RA   Khalili-Shirazi A., Clarke A.R., Hasnain S.S., Collinge J.;
RT   "Crystal structure of human prion protein bound to a therapeutic
RT   antibody.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2554-2558(2009).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 125-227 OF VARIANT VAL-129;
RP   VARIANT FFI/CJD ASN-178 AND VARIANT GSD SER-198, SUBUNIT, AND DOMAIN.
RX   PubMed=19927125; DOI=10.1038/emboj.2009.333;
RA   Lee S., Antony L., Hartmann R., Knaus K.J., Surewicz K.,
RA   Surewicz W.K., Yee V.C.;
RT   "Conformational diversity in prion protein variants influences
RT   intermolecular beta-sheet formation.";
RL   EMBO J. 29:251-262(2010).
RN   [36]
RP   VARIANT GSD LEU-102.
RX   PubMed=2564168; DOI=10.1038/338342a0;
RA   Hsiao K., Baker H.F., Crow T.J., Poulter M., Owen F.,
RA   Terwilliger J.D., Westaway D., Ott J., Pursiner S.B.;
RT   "Linkage of a prion protein missense variant to Gerstmann-Straussler
RT   syndrome.";
RL   Nature 338:342-345(1989).
RN   [37]
RP   VARIANTS LEU-102; VAL-117 AND VAL-129.
RX   PubMed=2783132; DOI=10.1016/0006-291X(89)92317-6;
RA   Doh-Ura K., Tateishi J., Sasaki H., Kitamoto T., Sakaki Y.;
RT   "Pro-->Leu change at position 102 of prion protein is the most common
RT   but not the sole mutation related to Gerstmann-Straussler syndrome.";
RL   Biochem. Biophys. Res. Commun. 163:974-979(1989).
RN   [38]
RP   VARIANT FFI ASN-178.
RX   PubMed=1347910; DOI=10.1212/WNL.42.3.669;
RA   Medori R., Montagna P., Tritschler H.J., Leblanc A., Cortelli P.,
RA   Tinuper P., Lugaresi E., Gambetti P.;
RT   "Fatal familial insomnia: a second kindred with mutation of prion
RT   protein gene at codon 178.";
RL   Neurology 42:669-670(1992).
RN   [39]
RP   VARIANT CJD ASN-178.
RX   PubMed=1671440; DOI=10.1016/0140-6736(91)91198-4;
RA   Goldfarb L.G., Haltia M., Brown P., Nieto A., Kovanen J.,
RA   McCombie W.R., Trapp S., Gajdusek D.C.;
RT   "New mutation in scrapie amyloid precursor gene (at codon 178) in
RT   Finnish Creutzfeldt-Jakob kindred.";
RL   Lancet 337:425-425(1991).
RN   [40]
RP   VARIANT CJD LYS-200.
RX   PubMed=1975028; DOI=10.1016/0140-6736(90)92073-Q;
RA   Goldfarb L., Mitrova E., Brown P., Toh B.K., Gajdusek D.C.;
RT   "Mutation in codon 200 of scrapie amyloid protein gene in two clusters
RT   of Creutzfeldt-Jakob disease in Slovakia.";
RL   Lancet 336:514-515(1990).
RN   [41]
RP   VARIANT GSD ARG-217.
RX   PubMed=1363810; DOI=10.1038/ng0492-68;
RA   Hsiao K., Dlouhy S.R., Farlow M.R., Cass C., da Costa M.,
RA   Conneally P.M., Hodes M.E., Ghetti B., Prusiner S.B.;
RT   "Mutant prion proteins in Gerstmann-Straussler-Scheinker disease with
RT   neurofibrillary tangles.";
RL   Nat. Genet. 1:68-71(1992).
RN   [42]
RP   VARIANTS CJD ILE-180 AND ARG-232.
RX   PubMed=8461023; DOI=10.1006/bbrc.1993.1275;
RA   Kitamoto T., Ohta M., Doh-Ura K., Hitoshi S., Terao Y., Tateishi J.;
RT   "Novel missense variants of prion protein in Creutzfeldt-Jakob disease
RT   or Gerstmann-Straussler syndrome.";
RL   Biochem. Biophys. Res. Commun. 191:709-714(1993).
RN   [43]
RP   VARIANT CJD ILE-210.
RX   PubMed=7902693; DOI=10.1002/ana.410340608;
RA   Pocchiari M., Salvatore M., Cutruzzola F., Genuardi M.,
RA   Allcatelli C.T., Masullo C., Macchi G., Alema G., Galgani S., Xi Y.G.,
RA   Petraroli R., Silvestrini M.C., Brunori M.;
RT   "A new point mutation of the prion protein gene in Creutzfeldt-Jakob
RT   disease.";
RL   Ann. Neurol. 34:802-807(1993).
RN   [44]
RP   VARIANT GSD LEU-105.
RX   PubMed=7902972; DOI=10.1212/WNL.43.12.2723-a;
RA   Yamada M., Itoh Y., Fujigasaki H., Naruse S., Kaneko K., Kitamoto T.,
RA   Tateishi J., Otomo E., Hayakawa M., Tanaka J., Matsushita M.,
RA   Miyatake T.;
RT   "A missense mutation at codon 105 with codon 129 polymorphism of the
RT   prion protein gene in a new variant of Gerstmann-Straussler-Scheinker
RT   disease.";
RL   Neurology 43:2723-2724(1993).
RN   [45]
RP   VARIANT GSD LEU-105.
RX   PubMed=7699395; DOI=10.1016/0022-510X(94)90138-4;
RA   Itoh Y., Yamada M., Hayakawa M., Shozawa T., Tanaka J., Matsushita M.,
RA   Kitamoto T., Tateishi J., Otomo E.;
RT   "A variant of Gerstmann-Straussler-Scheinker disease carrying codon
RT   105 mutation with codon 129 polymorphism of the prion protein gene: a
RT   clinicopathological study.";
RL   J. Neurol. Sci. 127:77-86(1994).
RN   [46]
RP   VARIANT CJD LYS-200.
RX   PubMed=7906019; DOI=10.1212/WNL.44.2.299;
RA   Inoue I., Kitamoto T., Doh-Ura K., Shii H., Goto I., Tateishi J.;
RT   "Japanese family with Creutzfeldt-Jakob disease with codon 200 point
RT   mutation of the prion protein gene.";
RL   Neurology 44:299-301(1994).
RN   [47]
RP   VARIANT CJD LYS-200.
RX   PubMed=7913755; DOI=10.1098/rstb.1994.0033;
RA   Gabizon R., Rosenman H., Meiner Z., Kahana I., Kahana E., Shugart Y.,
RA   Ott J., Prusiner S.B.;
RT   "Mutation in codon 200 and polymorphism in codon 129 of the prion
RT   protein gene in Libyan Jews with Creutzfeldt-Jakob disease.";
RL   Philos. Trans. R. Soc. Lond., B, Biol. Sci. 343:385-390(1994).
RN   [48]
RP   VARIANT GSD LEU-102.
RX   PubMed=7783876; DOI=10.1212/WNL.45.6.1127;
RA   Young K., Jones C.K., Piccardo P., Lazzarini A., Golbe L.I.,
RA   Zimmerman T.R., Dickson D.W., McLachlan D.C., St George-Hyslop P.H.,
RA   Lennox A.;
RT   "Gerstmann-Straussler-Scheinker disease with mutation at codon 102 and
RT   methionine at codon 129 of PRNP in previously unreported patients.";
RL   Neurology 45:1127-1134(1995).
RN   [49]
RP   VARIANT GSD LEU-102, AND VARIANT LYS-219.
RX   PubMed=8797472; DOI=10.1212/WNL.47.3.734;
RA   Barbanti P., Fabbrini G., Salvatore M., Petraroli R., Cardone F.,
RA   Maras B., Equestre M., Macchi G., Lenzi G.L., Pocchiari M.;
RT   "Polymorphism at codon 129 or codon 219 of PRNP and clinical
RT   heterogeneity in a previously unreported family with Gerstmann-
RT   Straussler-Scheinker disease (PrP-P102L mutation).";
RL   Neurology 47:734-741(1996).
RN   [50]
RP   VARIANT CJD HIS-208.
RX   PubMed=8909447; DOI=10.1212/WNL.47.5.1305;
RA   Mastrianni J.A., Iannicola C., Myers R.M., Dearmond S., Prusiner S.B.;
RT   "Mutation of the prion protein gene at codon 208 in familial
RT   Creutzfeldt-Jakob disease.";
RL   Neurology 47:1305-1312(1996).
RN   [51]
RP   VARIANT CJD HIS-208.
RX   PubMed=9266722; DOI=10.1002/ana.410420203;
RA   Nitrini R., Rosemberg S., Passos-Bueno M.R., da Silva L.S.,
RA   Iughetti P., Papadopoulos M., Carrilho P.M., Caramelli P.,
RA   Albrecht S., Zatz M., Leblanc A.;
RT   "Familial spongiform encephalopathy associated with a novel prion
RT   protein gene mutation.";
RL   Ann. Neurol. 42:138-146(1997).
RN   [52]
RP   VARIANTS GSD ASN-202 AND PRO-212.
RX   PubMed=9786248; DOI=10.1097/00005072-199810000-00010;
RA   Piccardo P., Dlouhy S.R., Lievens P.M., Young K., Bird T.D.,
RA   Nochlin D., Dickson D.W., Vinters H.V., Zimmerman T.R.,
RA   Mackenzie I.R., Kish S.J., Ang L.C., De Carli C., Pocchiari M.,
RA   Brown P., Gibbs C.J. Jr., Gajdusek D.C., Bugiani O., Ironside J.,
RA   Tagliavini F., Ghetti B.;
RT   "Phenotypic variability of Gerstmann-Straussler-Scheinker disease is
RT   associated with prion protein heterogeneity.";
RL   J. Neuropathol. Exp. Neurol. 57:979-988(1998).
RN   [53]
RP   VARIANTS ARG-188 AND SER-238.
RX   PubMed=10987652; DOI=10.1007/s004390051096;
RA   Windl O., Giese A., Schulz-Schaeffer W., Zerr I., Skworc K.,
RA   Arendt S., Oberdieck C., Bodemer M., Poser S., Kretzschmar H.A.;
RT   "Molecular genetics of human prion diseases in Germany.";
RL   Hum. Genet. 105:244-252(1999).
RN   [54]
RP   VARIANTS EARLY-ONSET DEMENTIA LEU-102; ALA-183 AND LYS-188.
RX   PubMed=10631141; DOI=10.1086/302702;
RA   Finckh U., Mueller-Thomsen T., Mann U., Eggers C., Marksteiner J.,
RA   Meins W., Binetti G., Alberici A., Hock C., Nitsch R.M., Gal A.;
RT   "High prevalence of pathogenic mutations in patients with early-onset
RT   dementia detected by sequence analyses of four different genes.";
RL   Am. J. Hum. Genet. 66:110-117(2000).
RN   [55]
RP   VARIANTS CJD LYS-196; ILE-203 AND GLN-211.
RX   PubMed=10790216;
RX   DOI=10.1002/(SICI)1098-1004(200005)15:5<482::AID-HUMU16>3.0.CO;2-1;
RA   Peoc'h K., Manivet P., Beaudry P., Attane F., Besson G., Didier H.,
RA   Delasnerie-Laupretre N., Laplanche J.-L.;
RT   "Identification of three novel mutations (E196K, V203I, E211Q) in the
RT   prion protein gene (PRNP) in inherited prion diseases with
RT   Creutzfeldt-Jakob disease phenotype.";
RL   Hum. Mutat. 15:482-482(2000).
RN   [56]
RP   VARIANT GSD VAL-131.
RX   PubMed=11709001; DOI=10.1001/archneur.58.11.1899;
RA   Panegyres P.K., Toufexis K., Kakulas B.A., Cernevakova L., Brown P.,
RA   Ghetti B., Piccardo P., Dlouhy S.R.;
RT   "A new PRNP mutation (G131V) associated with Gerstmann-Straussler-
RT   Scheinker disease.";
RL   Arch. Neurol. 58:1899-1902(2001).
CC   -!- FUNCTION: May play a role in neuronal development and synaptic
CC       plasticity. May be required for neuronal myelin sheath
CC       maintenance. May play a role in iron uptake and iron homeostasis.
CC       Soluble oligomers are toxic to cultured neuroblastoma cells and
CC       induce apoptosis (in vitro). Association with GPC1 (via its
CC       heparan sulfate chains) targets PRNP to lipid rafts. Also provides
CC       Cu(2+) or ZN(2+) for the ascorbate-mediated GPC1 deaminase
CC       degradation of its heparan sulfate side chains (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Monomer and homodimer. Has a tendency to aggregate into
CC       amyloid fibrils containing a cross-beta spine, formed by a steric
CC       zipper of superposed beta-strands. Soluble oligomers may represent
CC       an intermediate stage on the path to fibril formation. Copper
CC       binding may promote oligomerization. Interacts with GRB2, APP,
CC       ERI3/PRNPIP and SYN1. Mislocalized cytosolically exposed PrP
CC       interacts with MGRN1; this interaction alters MGRN1 subcellular
CC       location and causes lysosomal enlargement (By similarity).
CC       Interacts with KIAA1191. {ECO:0000250,
CC       ECO:0000269|PubMed:11524679, ECO:0000269|PubMed:11900542,
CC       ECO:0000269|PubMed:14623188, ECO:0000269|PubMed:17468747,
CC       ECO:0000269|PubMed:19204296, ECO:0000269|PubMed:19927125,
CC       ECO:0000269|PubMed:20375014, ECO:0000269|PubMed:20564047,
CC       ECO:0000269|PubMed:21153684}.
CC   -!- INTERACTION:
CC       Self; NbExp=17; IntAct=EBI-977302, EBI-977302;
CC       P05067:APP; NbExp=3; IntAct=EBI-977302, EBI-77613;
CC       P05067-4:APP; NbExp=2; IntAct=EBI-977302, EBI-302641;
CC       Q9BSJ6:FAM64A; NbExp=5; IntAct=EBI-977302, EBI-2568609;
CC       P31424-2:Grm5 (xeno); NbExp=4; IntAct=EBI-8830282, EBI-8830305;
CC       P49639:HOXA1; NbExp=4; IntAct=EBI-977302, EBI-740785;
CC       P10636:MAPT; NbExp=2; IntAct=EBI-977302, EBI-366182;
CC       P29372:MPG; NbExp=4; IntAct=EBI-977302, EBI-1043398;
CC       P52480:Pkm (xeno); NbExp=5; IntAct=EBI-8830282, EBI-647785;
CC       Q9H4B4:PLK3; NbExp=4; IntAct=EBI-977302, EBI-751877;
CC       P10279:PRNP (xeno); NbExp=5; IntAct=EBI-977302, EBI-7430632;
CC       P23907:PRNP (xeno); NbExp=3; IntAct=EBI-977302, EBI-7670302;
CC       P04925:Prnp (xeno); NbExp=3; IntAct=EBI-977302, EBI-768613;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor.
CC       Golgi apparatus. Note=Targeted to lipid rafts via association with
CC       the heparan sulfate chains of GPC1. Colocates, in the presence of
CC       CU(2+), to vesicles in para- and perinuclear regions, where both
CC       proteins undergo internalization. Heparin displaces PRNP from
CC       lipid rafts and promotes endocytosis.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC       Note=Accumulates outside the secretory route in the cytoplasm,
CC       from where it relocates to the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=PrP;
CC         IsoId=P04156-1; Sequence=Displayed;
CC       Name=2; Synonyms=PrP(M8);
CC         IsoId=P04156-2; Sequence=VSP_039045;
CC       Name=3; Synonyms=AltPrP;
CC         IsoId=F7VJQ1-1; Sequence=External;
CC   -!- DOMAIN: The normal, monomeric form, PRPN(C), has a mainly alpha-
CC       helical structure. Misfolding of this form produces a disease-
CC       associated, protease-resistant form, PRPN (Sc), accompanied by a
CC       large increase of the beta-sheet content and formation of amyloid
CC       fibrils. These fibrils consist of a cross-beta spine, formed by a
CC       steric zipper of superposed beta-strands. Disease mutations may
CC       favor intermolecular contacts via short beta strands, and may
CC       thereby trigger oligomerization. In addition, the heparan-sulfate
CC       proteoglycan, GPC1, promotes the association of PRPN (C) to lipid
CC       rafts and appears to facilitate the conversion to PRPN (Sc).
CC   -!- DOMAIN: Contains an N-terminal region composed of octamer repeats.
CC       At low copper concentrations, the sidechains of His residues from
CC       three or four repeats contribute to the binding of a single copper
CC       ion. Alternatively, a copper ion can be bound by interaction with
CC       the sidechain and backbone amide nitrogen of a single His residue.
CC       The observed copper binding stoichiometry suggests that two repeat
CC       regions cooperate to stabilize the binding of a single copper ion.
CC       At higher copper concentrations, each octamer can bind one copper
CC       ion by interactions with the His sidechain and Gly backbone atoms.
CC       A mixture of binding types may occur, especially in the case of
CC       octamer repeat expansion. Copper binding may stabilize the
CC       conformation of this region and may promote oligomerization.
CC   -!- PTM: The glycosylation pattern (the amount of mono-, di- and non-
CC       glycosylated forms or glycoforms) seems to differ in normal and
CC       CJD prion. {ECO:0000269|PubMed:19349973}.
CC   -!- PTM: Isoform 2 is sumoylated with SUMO1. {ECO:0000250}.
CC   -!- POLYMORPHISM: The five tandem octapeptide repeats region is highly
CC       unstable. Insertions or deletions of octapeptide repeat units are
CC       associated to prion disease.
CC   -!- DISEASE: Note=PrP is found in high quantity in the brain of humans
CC       and animals infected with neurodegenerative diseases known as
CC       transmissible spongiform encephalopathies or prion diseases, like:
CC       Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI),
CC       Gerstmann-Straussler disease (GSD), Huntington disease-like type 1
CC       (HDL1) and kuru in humans; scrapie in sheep and goat; bovine
CC       spongiform encephalopathy (BSE) in cattle; transmissible mink
CC       encephalopathy (TME); chronic wasting disease (CWD) of mule deer
CC       and elk; feline spongiform encephalopathy (FSE) in cats and exotic
CC       ungulate encephalopathy (EUE) in nyala and greater kudu. The prion
CC       diseases illustrate three manifestations of CNS degeneration: (1)
CC       infectious (2) sporadic and (3) dominantly inherited forms. TME,
CC       CWD, BSE, FSE, EUE are all thought to occur after consumption of
CC       prion-infected foodstuffs.
CC   -!- DISEASE: Creutzfeldt-Jakob disease (CJD) [MIM:123400]: Occurs
CC       primarily as a sporadic disorder (1 per million), while 10-15% are
CC       familial. Accidental transmission of CJD to humans appears to be
CC       iatrogenic (contaminated human growth hormone (HGH), corneal
CC       transplantation, electroencephalographic electrode implantation,
CC       etc.). Epidemiologic studies have failed to implicate the
CC       ingestion of infected animal meat in the pathogenesis of CJD in
CC       human. The triad of microscopic features that characterize the
CC       prion diseases consists of (1) spongiform degeneration of neurons,
CC       (2) severe astrocytic gliosis that often appears to be out of
CC       proportion to the degree of nerve cell loss, and (3) amyloid
CC       plaque formation. CJD is characterized by progressive dementia and
CC       myoclonic seizures, affecting adults in mid-life. Some patients
CC       present sleep disorders, abnormalities of high cortical function,
CC       cerebellar and corticospinal disturbances. The disease ends in
CC       death after a 3-12 months illness. {ECO:0000269|PubMed:10790216,
CC       ECO:0000269|PubMed:1671440, ECO:0000269|PubMed:1975028,
CC       ECO:0000269|PubMed:7902693, ECO:0000269|PubMed:7906019,
CC       ECO:0000269|PubMed:7913755, ECO:0000269|PubMed:8461023,
CC       ECO:0000269|PubMed:8909447, ECO:0000269|PubMed:9266722}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Fatal familial insomnia (FFI) [MIM:600072]: Autosomal
CC       dominant disorder and is characterized by neuronal degeneration
CC       limited to selected thalamic nuclei and progressive insomnia.
CC       {ECO:0000269|PubMed:1347910}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Gerstmann-Straussler disease (GSD) [MIM:137440]: A rare
CC       inherited prion disease characterized by adult onset of memory
CC       loss, dementia, ataxia, and pathologic deposition of amyloid-like
CC       plaques in the brain. GSD presents with progressive limb and
CC       truncal ataxia, dysarthria, and cognitive decline in the thirties
CC       and forties, and the average disease duration is 7 years.
CC       {ECO:0000269|PubMed:10581485, ECO:0000269|PubMed:11709001,
CC       ECO:0000269|PubMed:1363810, ECO:0000269|PubMed:2564168,
CC       ECO:0000269|PubMed:7699395, ECO:0000269|PubMed:7783876,
CC       ECO:0000269|PubMed:7902972, ECO:0000269|PubMed:8797472,
CC       ECO:0000269|PubMed:9786248}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Huntington disease-like 1 (HDL1) [MIM:603218]: Autosomal
CC       dominant, early-onset neurodegenerative disorder with prominent
CC       psychiatric features. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Kuru (KURU) [MIM:245300]: Kuru is transmitted during
CC       ritualistic cannibalism, among natives of the New Guinea
CC       highlands. Patients exhibit various movement disorders like
CC       cerebellar abnormalities, rigidity of the limbs, and clonus.
CC       Emotional lability is present, and dementia is conspicuously
CC       absent. Death usually occurs from 3 to 12 month after onset.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Spongiform encephalopathy with neuropsychiatric features
CC       (SENF) [MIM:606688]: Autosomal dominant presenile dementia with a
CC       rapidly progressive and protracted clinical course. The dementia
CC       was characterized clinically by frontotemporal features, including
CC       early personality changes. Some patients had memory loss, several
CC       showed aggressiveness, hyperorality and verbal stereotypy, others
CC       had parkinsonian symptoms. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: This protein is produced by a bicistronic gene
CC       which also produces the The alternative prion protein/AltPrP from
CC       an overlapping reading frame.
CC   -!- MISCELLANEOUS: The alternative prion protein/AltPrP (AC F7VJQ1)
CC       and PRNP have no apparent direct functional relation since a
CC       mutation that removes the start codon of the AltPrP has no
CC       apparent effect on the biology of PRNP. In mouse and hamster, the
CC       alternative initiation AUG codon is absent and is replaced by a
CC       GUG codon.
CC   -!- SIMILARITY: Belongs to the prion family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=The Official Mad Cow Disease Home Page;
CC       URL="http://www.mad-cow.org/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=PRNP entry;
CC       URL="http://en.wikipedia.org/wiki/PRNP";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13899; AAA60182.1; -; mRNA.
DR   EMBL; X83416; CAA58442.1; -; Genomic_DNA.
DR   EMBL; U29185; AAC78725.1; -; Genomic_DNA.
DR   EMBL; AF076976; AAD46098.1; -; Genomic_DNA.
DR   EMBL; AY008282; AAG21693.1; -; mRNA.
DR   EMBL; DQ408531; ABD63004.1; -; Genomic_DNA.
DR   EMBL; AL133396; CAB75503.1; -; Genomic_DNA.
DR   EMBL; AL133396; CAI19053.1; -; Genomic_DNA.
DR   EMBL; BC012844; AAH12844.1; -; mRNA.
DR   EMBL; BC022532; AAH22532.1; -; mRNA.
DR   EMBL; D00015; BAA00011.1; -; mRNA.
DR   EMBL; M13667; AAA19664.1; -; mRNA.
DR   EMBL; M81929; AAB59442.1; -; Genomic_DNA.
DR   EMBL; M81930; AAB59443.1; -; Genomic_DNA.
DR   EMBL; AF030575; AAC05365.1; -; Genomic_DNA.
DR   EMBL; S80732; AAB50648.2; -; Genomic_DNA.
DR   EMBL; S80743; AAB50649.2; -; Genomic_DNA.
DR   EMBL; S71208; AAB20521.1; -; Genomic_DNA.
DR   EMBL; S71210; AAB20522.1; -; Genomic_DNA.
DR   EMBL; S71212; AAB20523.1; -; Genomic_DNA.
DR   CCDS; CCDS13080.1; -. [P04156-1]
DR   PIR; A24173; UJHU.
DR   RefSeq; NP_000302.1; NM_000311.3. [P04156-1]
DR   RefSeq; NP_001073590.1; NM_001080121.1. [P04156-1]
DR   RefSeq; NP_001073591.1; NM_001080122.1. [P04156-1]
DR   RefSeq; NP_001073592.1; NM_001080123.1. [P04156-1]
DR   RefSeq; NP_898902.1; NM_183079.2. [P04156-1]
DR   UniGene; Hs.472010; -.
DR   UniGene; Hs.610285; -.
DR   UniGene; Hs.721670; -.
DR   PDB; 1E1G; NMR; -; A=125-228.
DR   PDB; 1E1J; NMR; -; A=125-228.
DR   PDB; 1E1P; NMR; -; A=125-228.
DR   PDB; 1E1S; NMR; -; A=125-228.
DR   PDB; 1E1U; NMR; -; A=125-228.
DR   PDB; 1E1W; NMR; -; A=125-228.
DR   PDB; 1FKC; NMR; -; A=90-231.
DR   PDB; 1FO7; NMR; -; A=90-231.
DR   PDB; 1H0L; NMR; -; A=121-230.
DR   PDB; 1HJM; NMR; -; A=125-228.
DR   PDB; 1HJN; NMR; -; A=125-228.
DR   PDB; 1I4M; X-ray; 2.00 A; A=119-226.
DR   PDB; 1OEH; NMR; -; A=77-84.
DR   PDB; 1OEI; NMR; -; A=61-84.
DR   PDB; 1QLX; NMR; -; A=23-230.
DR   PDB; 1QLZ; NMR; -; A=23-230.
DR   PDB; 1QM0; NMR; -; A=90-230.
DR   PDB; 1QM1; NMR; -; A=90-230.
DR   PDB; 1QM2; NMR; -; A=121-230.
DR   PDB; 1QM3; NMR; -; A=121-230.
DR   PDB; 2IV4; NMR; -; A=180-195.
DR   PDB; 2IV5; NMR; -; A=173-195.
DR   PDB; 2IV6; NMR; -; A=173-195.
DR   PDB; 2K1D; NMR; -; A=90-231.
DR   PDB; 2KUN; NMR; -; A=90-231.
DR   PDB; 2LBG; NMR; -; A=110-136.
DR   PDB; 2LEJ; NMR; -; A=90-231.
DR   PDB; 2LFT; NMR; -; A=90-231.
DR   PDB; 2LSB; NMR; -; A=90-231.
DR   PDB; 2LV1; NMR; -; A=90-231.
DR   PDB; 2M8T; NMR; -; A=90-231.
DR   PDB; 2OL9; X-ray; 0.85 A; A=170-175.
DR   PDB; 2W9E; X-ray; 2.90 A; A=119-231.
DR   PDB; 3HAF; X-ray; 2.26 A; A=90-231.
DR   PDB; 3HAK; X-ray; 1.80 A; A=125-227.
DR   PDB; 3HEQ; X-ray; 1.80 A; A/B=90-231.
DR   PDB; 3HER; X-ray; 1.85 A; A/B=90-231.
DR   PDB; 3HES; X-ray; 2.00 A; A/B=90-231.
DR   PDB; 3HJ5; X-ray; 3.10 A; A/B=90-231.
DR   PDB; 3HJX; X-ray; 2.00 A; A=126-231.
DR   PDB; 3MD4; X-ray; 1.15 A; A/B=127-132.
DR   PDB; 3MD5; X-ray; 1.40 A; A/B=127-132.
DR   PDB; 3NHC; X-ray; 1.57 A; A/B=127-132.
DR   PDB; 3NHD; X-ray; 1.92 A; A/B=127-132.
DR   PDB; 3NVF; X-ray; 1.80 A; A=138-143.
DR   PDB; 4DGI; X-ray; 2.40 A; A=120-230.
DR   PDB; 4E1H; X-ray; 1.40 A; A/C/E/G/I/K=177-182, B/D/F/H/J/L=211-216.
DR   PDB; 4E1I; X-ray; 2.03 A; A/C/E/G/I/K=177-182, B/D/F/H/J/L=211-216.
DR   PDB; 4KML; X-ray; 1.50 A; A=24-231.
DR   PDB; 4N9O; X-ray; 1.50 A; A=90-231.
DR   PDBsum; 1E1G; -.
DR   PDBsum; 1E1J; -.
DR   PDBsum; 1E1P; -.
DR   PDBsum; 1E1S; -.
DR   PDBsum; 1E1U; -.
DR   PDBsum; 1E1W; -.
DR   PDBsum; 1FKC; -.
DR   PDBsum; 1FO7; -.
DR   PDBsum; 1H0L; -.
DR   PDBsum; 1HJM; -.
DR   PDBsum; 1HJN; -.
DR   PDBsum; 1I4M; -.
DR   PDBsum; 1OEH; -.
DR   PDBsum; 1OEI; -.
DR   PDBsum; 1QLX; -.
DR   PDBsum; 1QLZ; -.
DR   PDBsum; 1QM0; -.
DR   PDBsum; 1QM1; -.
DR   PDBsum; 1QM2; -.
DR   PDBsum; 1QM3; -.
DR   PDBsum; 2IV4; -.
DR   PDBsum; 2IV5; -.
DR   PDBsum; 2IV6; -.
DR   PDBsum; 2K1D; -.
DR   PDBsum; 2KUN; -.
DR   PDBsum; 2LBG; -.
DR   PDBsum; 2LEJ; -.
DR   PDBsum; 2LFT; -.
DR   PDBsum; 2LSB; -.
DR   PDBsum; 2LV1; -.
DR   PDBsum; 2M8T; -.
DR   PDBsum; 2OL9; -.
DR   PDBsum; 2W9E; -.
DR   PDBsum; 3HAF; -.
DR   PDBsum; 3HAK; -.
DR   PDBsum; 3HEQ; -.
DR   PDBsum; 3HER; -.
DR   PDBsum; 3HES; -.
DR   PDBsum; 3HJ5; -.
DR   PDBsum; 3HJX; -.
DR   PDBsum; 3MD4; -.
DR   PDBsum; 3MD5; -.
DR   PDBsum; 3NHC; -.
DR   PDBsum; 3NHD; -.
DR   PDBsum; 3NVF; -.
DR   PDBsum; 4DGI; -.
DR   PDBsum; 4E1H; -.
DR   PDBsum; 4E1I; -.
DR   PDBsum; 4KML; -.
DR   PDBsum; 4N9O; -.
DR   DisProt; DP00466; -.
DR   ProteinModelPortal; P04156; -.
DR   SMR; P04156; 2-28, 90-231.
DR   BioGrid; 111606; 59.
DR   DIP; DIP-29933N; -.
DR   IntAct; P04156; 88.
DR   MINT; MINT-1420984; -.
DR   STRING; 9606.ENSP00000368752; -.
DR   BindingDB; P04156; -.
DR   ChEMBL; CHEMBL4869; -.
DR   DrugBank; DB00759; Tetracycline.
DR   PhosphoSite; P04156; -.
DR   BioMuta; PRNP; -.
DR   DMDM; 130912; -.
DR   MaxQB; P04156; -.
DR   PaxDb; P04156; -.
DR   PRIDE; P04156; -.
DR   DNASU; 5621; -.
DR   Ensembl; ENST00000379440; ENSP00000368752; ENSG00000171867.
DR   Ensembl; ENST00000430350; ENSP00000399376; ENSG00000171867.
DR   GeneID; 5621; -.
DR   KEGG; hsa:5621; -.
DR   UCSC; uc002wkt.1; human. [P04156-1]
DR   CTD; 5621; -.
DR   GeneCards; GC20P004615; -.
DR   GeneReviews; PRNP; -.
DR   HGNC; HGNC:9449; PRNP.
DR   HPA; HPA042754; -.
DR   HPA; HPA043398; -.
DR   MIM; 123400; phenotype.
DR   MIM; 137440; phenotype.
DR   MIM; 176640; gene.
DR   MIM; 245300; phenotype.
DR   MIM; 600072; phenotype.
DR   MIM; 603218; phenotype.
DR   MIM; 606688; phenotype.
DR   neXtProt; NX_P04156; -.
DR   Orphanet; 397606; Chronic diarrhea with hereditary sensory and autonomic neuropathy.
DR   Orphanet; 280397; Familial Alzheimer-like prion disease.
DR   Orphanet; 466; Fatal familial insomnia.
DR   Orphanet; 356; Gerstmann-Straussler-Scheinker syndrome.
DR   Orphanet; 157941; Huntington disease-like 1.
DR   Orphanet; 282166; Inherited Creutzfeldt-Jakob disease.
DR   PharmGKB; PA33796; -.
DR   eggNOG; NOG41716; -.
DR   GeneTree; ENSGT00510000049083; -.
DR   HOVERGEN; HBG008260; -.
DR   InParanoid; P04156; -.
DR   KO; K05634; -.
DR   OMA; HNPGYPH; -.
DR   OrthoDB; EOG7DRJ4Q; -.
DR   PhylomeDB; P04156; -.
DR   TreeFam; TF105188; -.
DR   Reactome; REACT_18312; NCAM1 interactions.
DR   ChiTaRS; PRNP; human.
DR   EvolutionaryTrace; P04156; -.
DR   GenomeRNAi; 5621; -.
DR   NextBio; 21844; -.
DR   PMAP-CutDB; P04156; -.
DR   PRO; PR:P04156; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; P04156; -.
DR   ExpressionAtlas; P04156; baseline and differential.
DR   Genevisible; P04156; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0019898; C:extrinsic component of membrane; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; NAS:UniProtKB.
DR   GO; GO:0071280; P:cellular response to copper ion; IDA:MGI.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0008152; P:metabolic process; TAS:ProtInc.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; ISS:BHF-UCL.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:BHF-UCL.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; ISS:BHF-UCL.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; ISS:BHF-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:InterPro.
DR   GO; GO:1901379; P:regulation of potassium ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0032880; P:regulation of protein localization; IEA:Ensembl.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; ISS:UniProtKB.
DR   Gene3D; 1.10.790.10; -; 1.
DR   InterPro; IPR000817; Prion.
DR   InterPro; IPR022416; Prion/Doppel_prot_b-ribbon_dom.
DR   InterPro; IPR025860; Prion_N_dom.
DR   PANTHER; PTHR11522; PTHR11522; 1.
DR   Pfam; PF00377; Prion; 1.
DR   Pfam; PF11587; Prion_bPrPp; 1.
DR   PRINTS; PR00341; PRION.
DR   SMART; SM00157; PRP; 1.
DR   SUPFAM; SSF54098; SSF54098; 1.
DR   PROSITE; PS00291; PRION_1; 1.
DR   PROSITE; PS00706; PRION_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Amyloid; Amyloidosis;
KW   Cell cycle; Cell membrane; Complete proteome; Copper; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Golgi apparatus; GPI-anchor; Growth arrest; Lipoprotein;
KW   Membrane; Metal-binding; Nucleus; Polymorphism; Prion;
KW   Reference proteome; Repeat; Signal; Ubl conjugation; Zinc.
FT   SIGNAL        1     22
FT   CHAIN        23    230       Major prion protein.
FT                                /FTId=PRO_0000025675.
FT   PROPEP      231    253       Removed in mature form. {ECO:0000250}.
FT                                /FTId=PRO_0000025676.
FT   REPEAT       51     59       1.
FT   REPEAT       60     67       2.
FT   REPEAT       68     75       3.
FT   REPEAT       76     83       4.
FT   REPEAT       84     91       5.
FT   REGION       23    230       Interaction with GRB2, ERI3 and SYN1.
FT                                {ECO:0000250}.
FT   REGION       51     91       5 X 8 AA tandem repeats of P-H-G-G-G-W-G-
FT                                Q.
FT   METAL        61     61       Copper or zinc 1.
FT   METAL        62     62       Copper or zinc 1; via amide nitrogen.
FT   METAL        63     63       Copper or zinc 1; via amide nitrogen and
FT                                carbonyl oxygen.
FT   METAL        69     69       Copper or zinc 2. {ECO:0000305}.
FT   METAL        70     70       Copper or zinc 2; via amide nitrogen.
FT                                {ECO:0000305}.
FT   METAL        71     71       Copper or zinc 2; via amide nitrogen and
FT                                carbonyl oxygen. {ECO:0000305}.
FT   METAL        77     77       Copper or zinc 3. {ECO:0000305}.
FT   METAL        78     78       Copper or zinc 3; via amide nitrogen.
FT                                {ECO:0000305}.
FT   METAL        79     79       Copper or zinc 3; via amide nitrogen and
FT                                carbonyl oxygen. {ECO:0000305}.
FT   METAL        85     85       Copper or zinc 4. {ECO:0000305}.
FT   METAL        86     86       Copper or zinc 4; via amide nitrogen.
FT                                {ECO:0000305}.
FT   METAL        87     87       Copper or zinc 4; via amide nitrogen and
FT                                carbonyl oxygen. {ECO:0000305}.
FT   LIPID       230    230       GPI-anchor amidated serine.
FT                                {ECO:0000250}.
FT   CARBOHYD    181    181       N-linked (GlcNAc...).
FT   CARBOHYD    197    197       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   DISULFID    179    214       {ECO:0000269|PubMed:14623188}.
FT   VAR_SEQ       1      7       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_039045.
FT   VARIANT      56     63       Missing. {ECO:0000269|PubMed:1363802,
FT                                ECO:0000269|PubMed:1678248,
FT                                ECO:0000269|PubMed:7485229}.
FT                                /FTId=VAR_013763.
FT   VARIANT     102    102       P -> L (in GSD and early-onset dementia).
FT                                {ECO:0000269|PubMed:10631141,
FT                                ECO:0000269|PubMed:2564168,
FT                                ECO:0000269|PubMed:2783132,
FT                                ECO:0000269|PubMed:7783876,
FT                                ECO:0000269|PubMed:8797472}.
FT                                /FTId=VAR_006464.
FT   VARIANT     105    105       P -> L (in GSD).
FT                                {ECO:0000269|PubMed:7699395,
FT                                ECO:0000269|PubMed:7902972}.
FT                                /FTId=VAR_006465.
FT   VARIANT     117    117       A -> V (linked to development of
FT                                dementing Gerstmann-Straussler disease).
FT                                {ECO:0000269|PubMed:2783132}.
FT                                /FTId=VAR_006466.
FT   VARIANT     129    129       M -> V (polymorphism; determines the
FT                                disease phenotype in patients who have a
FT                                PrP mutation at position 178. Patients
FT                                with M-129 develop FFI, those with V-129
FT                                develop CJD; dbSNP:rs1799990).
FT                                {ECO:0000269|PubMed:2783132}.
FT                                /FTId=VAR_006467.
FT   VARIANT     131    131       G -> V (in GSD).
FT                                {ECO:0000269|PubMed:11709001}.
FT                                /FTId=VAR_014264.
FT   VARIANT     171    171       N -> S (in schizoaffective disorder;
FT                                dbSNP:rs16990018).
FT                                {ECO:0000269|PubMed:9384372}.
FT                                /FTId=VAR_006468.
FT   VARIANT     178    178       D -> N (in FFI and CJD).
FT                                {ECO:0000269|PubMed:1347910,
FT                                ECO:0000269|PubMed:1671440}.
FT                                /FTId=VAR_006469.
FT   VARIANT     180    180       V -> I (in CJD).
FT                                {ECO:0000269|PubMed:8461023}.
FT                                /FTId=VAR_006470.
FT   VARIANT     183    183       T -> A (in familial spongiform
FT                                encephalopathy).
FT                                {ECO:0000269|PubMed:10631141}.
FT                                /FTId=VAR_006471.
FT   VARIANT     187    187       H -> R (in GSD).
FT                                {ECO:0000269|PubMed:10581485}.
FT                                /FTId=VAR_008746.
FT   VARIANT     188    188       T -> K (in early-onset dementia; dementia
FT                                associated to prion diseases).
FT                                {ECO:0000269|PubMed:10631141}.
FT                                /FTId=VAR_008748.
FT   VARIANT     188    188       T -> R. {ECO:0000269|PubMed:10987652}.
FT                                /FTId=VAR_008747.
FT   VARIANT     196    196       E -> K (in CJD).
FT                                {ECO:0000269|PubMed:10790216}.
FT                                /FTId=VAR_008749.
FT   VARIANT     198    198       F -> S (in GSD; atypical form with
FT                                neurofibrillary tangles).
FT                                {ECO:0000269|PubMed:19927125}.
FT                                /FTId=VAR_006472.
FT   VARIANT     200    200       E -> K (in CJD).
FT                                {ECO:0000269|PubMed:1975028,
FT                                ECO:0000269|PubMed:7906019,
FT                                ECO:0000269|PubMed:7913755}.
FT                                /FTId=VAR_006473.
FT   VARIANT     202    202       D -> N (in GSD).
FT                                {ECO:0000269|PubMed:9786248}.
FT                                /FTId=VAR_008750.
FT   VARIANT     203    203       V -> I (in CJD; it could be an extremely
FT                                rare polymorphism).
FT                                {ECO:0000269|PubMed:10790216}.
FT                                /FTId=VAR_008751.
FT   VARIANT     208    208       R -> H (in CJD).
FT                                {ECO:0000269|PubMed:8909447,
FT                                ECO:0000269|PubMed:9266722}.
FT                                /FTId=VAR_006474.
FT   VARIANT     210    210       V -> I (in CJD).
FT                                {ECO:0000269|PubMed:7902693}.
FT                                /FTId=VAR_006475.
FT   VARIANT     211    211       E -> Q (in CJD).
FT                                {ECO:0000269|PubMed:10790216}.
FT                                /FTId=VAR_008752.
FT   VARIANT     212    212       Q -> P (in GSD).
FT                                {ECO:0000269|PubMed:9786248}.
FT                                /FTId=VAR_008753.
FT   VARIANT     217    217       Q -> R (in GSD; with neurofibrillary
FT                                tangles). {ECO:0000269|PubMed:1363810}.
FT                                /FTId=VAR_006476.
FT   VARIANT     219    219       E -> K (in dbSNP:rs1800014).
FT                                {ECO:0000269|PubMed:8797472}.
FT                                /FTId=VAR_006477.
FT   VARIANT     232    232       M -> R (in CJD).
FT                                {ECO:0000269|PubMed:8461023}.
FT                                /FTId=VAR_006478.
FT   VARIANT     238    238       P -> S. {ECO:0000269|PubMed:10987652}.
FT                                /FTId=VAR_008754.
FT   MUTAGEN       1      1       M->S: Protein detected. No protein
FT                                detected; when associated with S-8.
FT                                {ECO:0000269|PubMed:19059915}.
FT   MUTAGEN       8      8       M->S: No protein detected; when
FT                                associated with S-1.
FT                                {ECO:0000269|PubMed:19059915}.
FT   CONFLICT    118    118       Missing (in Ref. 9; AAA19664/BAA00011).
FT                                {ECO:0000305}.
FT   CONFLICT    169    169       Y -> H (in Ref. 6; ABD63004).
FT                                {ECO:0000305}.
FT   CONFLICT    227    227       Q -> K (in Ref. 8; AAH22532).
FT                                {ECO:0000305}.
FT   STRAND       63     67       {ECO:0000244|PDB:1OEI}.
FT   STRAND       70     73       {ECO:0000244|PDB:1OEI}.
FT   TURN         74     76       {ECO:0000244|PDB:1OEI}.
FT   STRAND       79     82       {ECO:0000244|PDB:1OEH}.
FT   STRAND      118    122       {ECO:0000244|PDB:4KML}.
FT   STRAND      125    127       {ECO:0000244|PDB:1H0L}.
FT   STRAND      128    131       {ECO:0000244|PDB:3MD4}.
FT   STRAND      141    143       {ECO:0000244|PDB:1E1S}.
FT   HELIX       144    153       {ECO:0000244|PDB:4KML}.
FT   HELIX       154    156       {ECO:0000244|PDB:4KML}.
FT   STRAND      159    163       {ECO:0000244|PDB:1E1U}.
FT   HELIX       166    168       {ECO:0000244|PDB:4KML}.
FT   TURN        171    173       {ECO:0000244|PDB:1QM0}.
FT   STRAND      178    181       {ECO:0000244|PDB:4E1H}.
FT   HELIX       185    187       {ECO:0000244|PDB:1E1P}.
FT   TURN        188    190       {ECO:0000244|PDB:1E1P}.
FT   TURN        193    195       {ECO:0000244|PDB:3HAK}.
FT   STRAND      212    215       {ECO:0000244|PDB:4E1H}.
FT   TURN        223    225       {ECO:0000244|PDB:3HER}.
FT   TURN        228    230       {ECO:0000244|PDB:2LFT}.
SQ   SEQUENCE   253 AA;  27661 MW;  43DB596BAAA66484 CRC64;
     MANLGCWMLV LFVATWSDLG LCKKRPKPGG WNTGGSRYPG QGSPGGNRYP PQGGGGWGQP
     HGGGWGQPHG GGWGQPHGGG WGQPHGGGWG QGGGTHSQWN KPSKPKTNMK HMAGAAAAGA
     VVGGLGGYML GSAMSRPIIH FGSDYEDRYY RENMHRYPNQ VYYRPMDEYS NQNNFVHDCV
     NITIKQHTVT TTTKGENFTE TDVKMMERVV EQMCITQYER ESQAYYQRGS SMVLFSSPPV
     ILLISFLIFL IVG
//
